Found: 33
Select item for more details and to access through your institution.
Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology.
- Published in:
- Rheumatology International, 2016, v. 36, n. 5, p. 613, doi. 10.1007/s00296-016-3444-0
- By:
- Publication type:
- Article
Work instability in rheumatoid arthritis patients from Argentina: prevalence and associated factors.
- Published in:
- Rheumatology International, 2015, v. 35, n. 1, p. 107, doi. 10.1007/s00296-014-3062-7
- By:
- Publication type:
- Article
Prevalence of positive ppd in a cohort of rheumatoid arthritis patients.
- Published in:
- Rheumatology International, 2010, v. 30, n. 5, p. 613, doi. 10.1007/s00296-009-1027-z
- By:
- Publication type:
- Article
Clinical scenarios-based guide for tofacitinib in rheumatoid arthritis.
- Published in:
- Therapeutic Advances in Chronic Disease, 2023, p. 1, doi. 10.1177/20406223231178273
- By:
- Publication type:
- Article
Impact of Tofacitinib on Components of the ACR Response Criteria: Post Hoc Analysis of Phase III and Phase IIIb/IV Trials.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Upadacitinib in Rheumatoid Arthritis: A Benefit–Risk Assessment Across a Phase III Program.
- Published in:
- Drug Safety, 2021, v. 44, n. 5, p. 515, doi. 10.1007/s40264-020-01036-w
- By:
- Publication type:
- Article
Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
- Published in:
- BioDrugs, 2018, v. 32, n. 3, p. 193, doi. 10.1007/s40259-018-0283-4
- By:
- Publication type:
- Article
Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis.
- Published in:
- Open Access Rheumatology: Research & Reviews, 2021, v. 13, p. 139, doi. 10.2147/OARRR.S282627
- By:
- Publication type:
- Article
Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis.
- Published in:
- Current Rheumatology Reports, 2018, v. 20, n. 12, p. 1, doi. 10.1007/s11926-018-0799-0
- By:
- Publication type:
- Article
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis.
- Published in:
- Current Rheumatology Reports, 2018, v. 20, n. 10, p. 1, doi. 10.1007/s11926-018-0769-6
- By:
- Publication type:
- Article
Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician.
- Published in:
- Current Rheumatology Reports, 2017, v. 19, n. 6, p. 1, doi. 10.1007/s11926-017-0658-4
- By:
- Publication type:
- Article
Biosimilars: Clinical Interpretation and Implications for Drug Development.
- Published in:
- Current Rheumatology Reports, 2015, v. 17, n. 2, p. 1, doi. 10.1007/s11926-014-0483-y
- By:
- Publication type:
- Article
Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis.
- Published in:
- Clinical Rheumatology, 2017, v. 36, n. 12, p. 2655, doi. 10.1007/s10067-017-3788-1
- By:
- Publication type:
- Article
Biosimilars in rheumatology: a view from Latin America.
- Published in:
- 2012
- By:
- Publication type:
- Editorial
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
- Published in:
- Drugs, 2021, v. 81, n. 16, p. 1859, doi. 10.1007/s40265-021-01610-1
- By:
- Publication type:
- Article
Safety of Upadacitinib in Immune-Mediated Inflammatory Diseases: Systematic Literature Review of Indirect and Direct Treatment Comparisons of Randomized Controlled Trials.
- Published in:
- Advances in Therapy, 2024, v. 41, n. 2, p. 567, doi. 10.1007/s12325-023-02732-6
- By:
- Publication type:
- Article
Opportunities and challenges of lupus care in Latin America, the Middle East, and Asia-Pacific: A call to action.
- Published in:
- Modern Rheumatology, 2024, v. 34, n. 4, p. 655, doi. 10.1093/mr/roae001
- By:
- Publication type:
- Article
Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials.
- Published in:
- Rheumatology & Therapy, 2024, v. 11, n. 5, p. 1135, doi. 10.1007/s40744-024-00677-y
- By:
- Publication type:
- Article
Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE.
- Published in:
- Rheumatology & Therapy, 2024, v. 11, n. 3, p. 599, doi. 10.1007/s40744-024-00658-1
- By:
- Publication type:
- Article
Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies.
- Published in:
- Rheumatology & Therapy, 2023, v. 10, n. 2, p. 463, doi. 10.1007/s40744-022-00529-7
- By:
- Publication type:
- Article
Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis.
- Published in:
- Rheumatology & Therapy, 2022, v. 9, n. 1, p. 191, doi. 10.1007/s40744-021-00399-5
- By:
- Publication type:
- Article
Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?
- Published in:
- Rheumatology & Therapy, 2020, v. 7, n. 1, p. 35, doi. 10.1007/s40744-019-00190-7
- By:
- Publication type:
- Article
Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE.
- Published in:
- Rheumatology, 2023, v. 62, n. 5, p. 1804, doi. 10.1093/rheumatology/keac477
- By:
- Publication type:
- Article
Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program.
- Published in:
- Rheumatology, 2022, v. 61, n. 8, p. 3246, doi. 10.1093/rheumatology/keab861
- By:
- Publication type:
- Article
Corrigendum to: Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Phase III trials of JAK1 selective inhibitors in rheumatoid arthritis.
- Published in:
- Rheumatology, 2021, v. 60, p. ii17, doi. 10.1093/rheumatology/keaa823
- By:
- Publication type:
- Article
Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials.
- Published in:
- Rheumatology, 2020, v. 59, n. 12, p. 3834, doi. 10.1093/rheumatology/keaa189
- By:
- Publication type:
- Article
Work Productivity in Rheumatoid Arthritis: Relationship with Clinical and Radiological Features.
- Published in:
- Arthritis (20901984), 2012, p. 1, doi. 10.1155/2012/137635
- By:
- Publication type:
- Article
Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk‐Enriched Rheumatoid Arthritis Patients.
- Published in:
- Arthritis & Rheumatology, 2024, v. 76, n. 8, p. 1218, doi. 10.1002/art.42846
- By:
- Publication type:
- Article
Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double‐Blind, Randomized Controlled Trial.
- Published in:
- Arthritis & Rheumatology, 2019, v. 71, n. 11, p. 1788, doi. 10.1002/art.41032
- By:
- Publication type:
- Article
The Efficacy and Safety of Subcutaneous Clazakizumab in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results From a Multinational, Phase IIb, Randomized, Double-Blind, Placebo/Active-Controlled...
- Published in:
- Arthritis & Rheumatology, 2015, v. 67, n. 10, p. 2591, doi. 10.1002/art.39249
- By:
- Publication type:
- Article
Similar and mimics: Latin America biosimilar regulations.
- Published in:
- 2019
- By:
- Publication type:
- Editorial